Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.81 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.81 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.81 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.81 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | DRD3 | P35462 | 1/20 | 0.81 |
| ▸ | XDH | P47989 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.47 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL3413249 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3416956 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL29442902 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL8111 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3414606 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL29982697 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL29466915 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL29355156 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL1331751 | 0.90 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL5062422 | 0.88 | PI4KA (0.96) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287408-A1 | NUCLEIC ACID CONSTRUCTS FOR DELIVERING POLYNUCLEOTIDES INTO EXOSOMES | RENEURON LIMITED (GB) | 2023-09-14 | — | — | US | claimed |
| WO-2023283548-A1 | SIGNAL ACTIVATABLE NUCLEIC ACID CONSTRUCTS WITH WOBBLE BASE PAIRINGS | SWITCH THERAPEUTICS INC. (US) | 2023-01-12 | — | — | WO | claimed |
| CN-114867855-A | Nucleic acid constructs for delivery of polynucleotides into exosomes | 兰诺龙有限公司 | 2022-08-05 | — | — | CN | claimed |
| WO-1993017035-A1 | 2'ISODIDEOXY-β-D-NUCLEOSIDES AS STABLE ANTIVIRAL AGENTS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-09-02 | — | — | WO | claimed |
| WO-2024137660-A2 | PROGRAMMABLE RNA EDITING IN PARKINSON'S DISEASE THERAPY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240200062-A1 | METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | PEPGEN INC. | 2024-06-20 | — | — | US | disclosed |
| CN-113874504-B | Nucleic acid construct and method for producing same | 莱特比奥有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240189434-A1 | METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | PEPGEN INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240182892-A1 | DOUBLE-STRANDED SIRNA HAVING PATTERNED CHEMICAL MODIFICATIONS | ATALANTA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240175016-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| WO-2024112809-A2 | CELL-PENETRATING PEPTIDES, CONJUGATES THEREOF, AND METHODS OF THEIR USE | PEPGEN INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240167060-A1 | COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES | CRISPR THERAPEUTICS AG (CH) | 2024-05-23 | — | — | US | disclosed |
| US-5273885-A | Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-4376825-A | ENZYME-BOUND LIGANDS WITH FREE REACTIVE SITES WHICH CAN BIND RECEPTORS | SYVA COMPANY (US) | 1983-03-15 | — | — | US | disclosed |
| US-4282325-A | FOR AMPLIFICATION IN ASSAYS | SYVA COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4203802-A | ENZYME BOUND TO AN ESTROGEN LIGAND | SYVA COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4190496-A | RECEPTOR, LIGAND, AND ENZYME-BOUND | SYVA COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4067774-A | Compounds for enzyme amplification assay | SYVA COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240200062-A1 | METHODS OF TREATING DUCHENNE MUSCULAR DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | MTPN, UTRN, MUSK | PI4KA 4759/4885PI4K2B 4691/4885PI4K2A 4728/4885 |
| US-20240182892-A1 | DOUBLE-STRANDED SIRNA HAVING PATTERNED CHEMICAL MODIFICATIONS | SNRPE, NSUN2, PHAX | PI4KA 712/4885PI4K2B 382/4885PI4K2A 317/4885 |
| US-20240189434-A1 | METHODS OF TREATING MYOTONIC DYSTROPHY TYPE 1 USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES | NPBWR1, HBB, HNRNPH3 | PI4KA 4298/4885PI4K2B 2614/4885PI4K2A 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.